Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 43.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,990 shares of the company's stock after selling 257,533 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.26% of Vaxcyte worth $12,687,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI bought a new position in shares of Vaxcyte during the 4th quarter worth $41,000. Assetmark Inc. grew its stake in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the period. Parallel Advisors LLC lifted its holdings in Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after purchasing an additional 1,071 shares in the last quarter. Finally, J.Safra Asset Management Corp lifted its holdings in Vaxcyte by 62.9% during the 4th quarter. J.Safra Asset Management Corp now owns 1,907 shares of the company's stock worth $156,000 after purchasing an additional 736 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Down 0.1%

Shares of Vaxcyte stock traded down $0.04 during midday trading on Friday, hitting $33.24. The company had a trading volume of 474,884 shares, compared to its average volume of 1,472,286. The stock has a market cap of $4.29 billion, a price-to-earnings ratio of -8.33 and a beta of 1.19. The company has a fifty day simple moving average of $33.32 and a 200 day simple moving average of $57.24. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period last year, the business earned ($0.85) EPS. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PCVX shares. The Goldman Sachs Group reduced their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.